查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2100178

強迫症治療市場－2026-2032年全球市場預測

Obsessive-Compulsive Disorder Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，強迫症 (OCD) 治療市場將成長至 19.1 億美元，複合年成長率為 8.91%。

主要市場統計數據
基準年 2025 10.5億美元
預計年份：2026年 11.3億美元
預測年份 2032 19.1億美元
複合年成長率 (%) 8.91%

強迫症（OCD）藥物治療在治療這種以侵入性思考和重複性行為為特徵的慢性、常伴隨生活破壞性的精神疾病中發揮核心作用。目前的藥物治療以選擇性血清素再回收抑制劑（SSRIs）為主，對於療效不佳或部分無效的患者，則採用氯米帕明和實證聯合治療。世界衛生組織（WHO）已將精神疾病列為全球致殘的主要原因之一，且同行評審的流行病學研究一​​致表明，強迫症通常在青少年或青年時期發病，需要長期治療，這些都進一步凸顯了強迫症藥物的臨床意義。

診斷率的提高、人們對心理健康意識的增強、遠距精神醫學的擴展以及藥物治療與認知行為療法（特別是暴露療法和反應預防）的更緊密結合，正在重塑行業格局。然而，仍有許多未被滿足的需求，包括診斷延遲、治療效果差異、不利事件負擔、復發風險、合併憂鬱症和焦慮症，以及資源匱乏地區醫療服務取得的不平等。隨著醫療系統向精準精神醫學轉型，強迫症藥物領域的相關人員正優先考慮差異化的作用機制、有助於提高用藥依從性的製劑、真實世界數據、數位監測以及以患者為中心的治療結果。

強迫症治療前景的變革性變化

強迫症（OCD）的治療領域正在經歷一場漸進但意義深遠的變革，從症狀抑制轉向更個人化、實證的治療路徑。雖然標準的血清素能療法仍然至關重要，但臨床實踐越來越注重早期識別難治性強迫症，並在指南支持的特定病例中應用結構化的增強治療方案，包括抗精神病藥物增強治療。這種轉變得益於標準化嚴重程度評估工具（例如耶魯-布朗強迫症量表）的日益普及，這些工具用於評估治療反應並指導治療最佳化。

人工智慧（AI）對強迫症（OCD）藥物研發的累積影響

人工智慧 (AI) 對強迫症治療生態系統的影響日益顯著，涵蓋藥物發現與研發、臨床實踐以及治療後監測等各個環節。在研究初期，AI 驅動的分析能夠輔助標靶辨識、文獻挖掘、分子篩檢，並探索除傳統血清素再攝取抑制之外的新型作用機制。在臨床開發階段，機器學習技術正被用於改善患者分層、識別合併症模式、最佳化臨床實驗參與者招募，以及檢測與治療反應和不利事件相關的訊號。

強迫症治療市場關鍵區域洞察

北美強迫症（OCD）藥物市場環境受益於許多因素，例如完善的精神病學指南、選擇性血清素再回收抑制劑（SSRIs）的廣泛應用、健全的專業精神衛生基礎設施，以及遠距遠端醫療在後續觀察和藥物管理方面的日益普及。儘管實證藥物治療聯合認知行為療法在美國和加拿大仍然十分重要，但保險公司的審查、保險體系的設計、當地的就醫障礙以及精神衛生專業人員的分佈都會影響治療的連續性。

小組對強迫症治療的取得和政策的主要見解。

在東南亞國協，隨著成員國擴大精神健康政策框架、提升都市區醫療保健能力以及普及非專利抗憂鬱症，強迫症（OCD）藥物治療的重要性日益凸顯。然而，診斷不足和精神科服務分佈不均仍影響著患者的治療接受度，尤其是在大都會圈以外的地區。在海灣合作理事會（GCC）國家，醫療保健現代化、保險體系的擴展以及對專業行為健康服務的投入，正在為強迫症的診斷和藥物治療創造更有利的途徑，但文化污名仍然是一個不容忽視的因素。

關於強迫症藥物引入的關鍵國家概況

美國在強迫症（OCD）藥物領域仍然具有舉足輕重的地位，這得益於其積極的臨床研究、廣泛使用基於指南的選擇性血清素再攝取抑製劑（SSRIs）、高普及率的遠距精神科醫療服務以及對難治性強迫症的積極應對。獲得治療的機會取決於保險覆蓋範圍、預先批准、專科醫生的可及性以及較高的合併症管理需求。在加拿大，儘管政府強調公共醫療保健、循證處方和綜合精神健康服務，但各省和地區在精神科醫療服務方面的差異影響了及時治療。在墨西哥，人們對價格低廉的學名藥的認知度和使用率正在提高，但獲得專科醫生服務和持續治療的機會仍然不均衡。

為強迫症製藥業的領導者提供的實用建議

產業領導者應優先考慮差異化治療方案，以解決強迫症治療中最持久的未滿足需求，例如治療反應不足、反應延遲、復發預防、性功能障礙、體重變化、鎮靜作用以及藥物依從性問題。研發計畫應納入檢驗的強迫症特異性終點指標、病患報告結局、合併症評估、安全性監測和長期追蹤研究，以證明其在真實世界臨床實踐中的相關性。

基於證據的強迫症治療藥物分析調查方法

本執行摘要採用基於檢驗的公共和科學資訊來源的系統性二手調查方法編寫而成。該研究途徑整合了同行評審的精神病學文獻、臨床實踐指南、監管公告、藥物警戒資料、公共衛生出版物、基本藥物參考資料和精神衛生政策文件的證據。尤其著重於基於數據的見解，包括疾病負擔、治療標準、藥物分類、取得途徑、監管考慮和當地醫療保健基礎設施等方面。

關於強迫症藥物未來發展的結論

強迫症（OCD）藥物治療領域正從傳統的以血清素為中心的治療模式發展到更整合和個人化的治療體系。雖然現有藥物仍然至關重要，但下一階段的產業發展將著重於更好地管理難治性強迫症、提高藥物耐受性、實現更快更持久的療效、產生真實世界數據（REW），以及加強藥物治療與行為治療之間的協作。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 強迫症治療市場：依藥物類別分類

  • MAOI
    • 芬納嗪
    • 反式環丙胺
  • SNRI
    • Desvenlafaxine
    • Duloxetine
    • 文拉法辛
  • SSRI
    • 西洛普魯姆
    • Fluoxetine
    • 氟伏沙明
    • 帕羅西汀
    • 舍曲林
  • TCA
    • 阿米替林
    • 氯米帕明
    • 丙咪嗪

第8章：強迫症治療市場：依通路分類

  • 離線
  • 線上
    • 電子商務網站
    • 製造商網站

第9章：強迫症治療市場：依給藥途徑分類

  • 口服
  • 腸外

第10章：強迫症治療市場：依最終使用者分類

  • 診所
  • 醫院
  • 普通家庭

第11章 強迫症治療市場：依治療類型分類

  • 單藥治療
  • 聯合治療
  • 輔助性治療

第12章 強迫症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 強迫症治療市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 強迫症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc
  • Alembic Pharmaceuticals Ltd
  • Amneal Pharmaceuticals Inc
  • Apotex Inc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc
  • Biohaven Ltd
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr Reddys Laboratories Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • H Lundbeck AS
  • Intas Pharmaceuticals Limited
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Lupin Ltd
  • Merck & Co Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Limited
  • Viatris Inc
  • Wockhardt Ltd
Product Code: MRR-742BD51822E2

The Obsessive-Compulsive Disorder Drugs Market is projected to grow by USD 1.91 billion at a CAGR of 8.91% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.05 billion
Estimated Year [2026] USD 1.13 billion
Forecast Year [2032] USD 1.91 billion
CAGR (%) 8.91%

Obsessive-compulsive disorder drugs are central to the treatment of a chronic and often disabling mental health condition characterized by intrusive thoughts and repetitive behaviors. Current pharmacotherapy is anchored by selective serotonin reuptake inhibitors, with clomipramine and evidence-based augmentation strategies used for patients with partial or inadequate response. The clinical relevance of the obsessive-compulsive disorder drugs landscape is reinforced by the World Health Organization's recognition of mental disorders as a major contributor to global disability, while peer-reviewed epidemiology consistently identifies OCD as a condition that frequently begins in adolescence or early adulthood and often requires long-term care.

The industry environment is shaped by rising diagnosis rates, improving mental health awareness, expanding telepsychiatry, and stronger integration of pharmacological treatment with cognitive behavioral therapy, particularly exposure and response prevention. At the same time, unmet needs remain substantial, including delayed diagnosis, variable treatment response, adverse-event burden, relapse risk, comorbid depression and anxiety, and access gaps across low-resource settings. As healthcare systems move toward precision psychiatry, stakeholders in obsessive-compulsive disorder therapeutics are prioritizing differentiated mechanisms, adherence-supportive formulations, real-world evidence, digital monitoring, and patient-centered outcomes.

Transformative Shifts in the OCD Therapeutics Landscape

The obsessive-compulsive disorder drugs landscape is undergoing a gradual but meaningful transformation from symptom suppression toward more individualized, evidence-informed treatment pathways. Standard serotonin-based therapies remain foundational, yet clinical practice is increasingly focused on identifying treatment-resistant OCD earlier and applying structured augmentation approaches, including antipsychotic augmentation in selected cases where supported by guidelines. This shift is supported by greater use of standardized severity tools, such as the Yale-Brown Obsessive Compulsive Scale, to evaluate response and guide therapy optimization.

Another major shift is the movement from episodic prescribing to integrated care models. Pharmacotherapy is increasingly coordinated with psychotherapy, digital behavioral support, remote follow-up, and comorbidity management. Regulators and payers are also emphasizing safety, adherence, pharmacovigilance, and real-world effectiveness rather than relying only on controlled trial endpoints. Meanwhile, scientific interest in glutamatergic modulation, neuroinflammation, rapid-acting neuropsychiatric approaches, and biomarker-guided treatment is broadening the future development agenda. These changes are creating a more competitive environment for OCD drug development, where clinical differentiation depends on tolerability, speed of response, relapse prevention, and effectiveness in patients who do not respond adequately to first-line therapies.

Cumulative Impact of Artificial Intelligence on OCD Drug Development

Artificial intelligence is increasingly influencing the obsessive-compulsive disorder drugs ecosystem across discovery, development, clinical operations, and post-treatment monitoring. In early research, AI-enabled analytics can support target identification, literature mining, molecular screening, and the exploration of novel mechanisms beyond conventional serotonin reuptake inhibition. In clinical development, machine learning methods are being applied to improve patient stratification, identify comorbidity patterns, optimize trial recruitment, and detect signals associated with treatment response or adverse events.

In care delivery, AI-supported tools can help clinicians monitor symptom trajectories, medication adherence, relapse indicators, and patient-reported outcomes between appointments. Natural language processing, when applied responsibly to clinical notes or structured patient inputs, may help identify severity changes, compulsive behavior patterns, or risk factors that require timely intervention. However, the cumulative impact of artificial intelligence depends on strong governance. OCD treatment involves sensitive behavioral and mental health data, making privacy protection, bias mitigation, clinical validation, explainability, and regulatory compliance essential. AI is therefore best positioned as a decision-support layer that strengthens evidence generation and continuity of care, not as a replacement for specialist clinical judgment.

Key Regional Insights Across the OCD Drugs Market

In North America, the obsessive-compulsive disorder drugs landscape benefits from established psychiatric guidelines, broad availability of selective serotonin reuptake inhibitors, specialist mental health infrastructure, and increasing use of telehealth for follow-up and medication management. The United States and Canada continue to emphasize evidence-based pharmacotherapy combined with cognitive behavioral therapy, while payer scrutiny, insurance design, rural access barriers, and mental health workforce distribution influence treatment continuity.

Europe is characterized by strong clinical governance, national health technology assessment processes, and high emphasis on safety monitoring, guideline adherence, and equitable mental health access. Countries across Western Europe have mature prescribing environments for OCD medications, while variation in reimbursement, psychotherapy waiting times, and mental health workforce capacity influences patient access across the wider region. Asia-Pacific is marked by rising recognition of OCD, expanding psychiatric services, digital health adoption, and growing demand for affordable pharmacological treatment, particularly in China, India, Japan, South Korea, Australia, and ASEAN economies. However, stigma, uneven specialist availability, and out-of-pocket expenditure continue to affect diagnosis and adherence in several settings.

Latin America shows increasing mental health awareness and expanding use of generic antidepressants, with Brazil and Mexico playing important roles in regional treatment access. Nonetheless, fragmented healthcare delivery, socioeconomic inequality, and variable specialist availability remain barriers to consistent OCD management. In the Middle East, investment in mental health infrastructure is improving access in Gulf economies, while awareness campaigns are helping reduce stigma and support earlier care-seeking. Across Africa, the OCD drugs landscape is shaped by significant access challenges, limited psychiatric workforce density in many countries, and dependence on essential medicines frameworks, making affordability, primary care integration, task-sharing, and community-based mental health services critical priorities.

Key Group Insights for OCD Drug Access and Policy

ASEAN is becoming increasingly relevant for obsessive-compulsive disorder drugs as member countries expand mental health policy frameworks, urban healthcare capacity, and access to generic antidepressants. However, diagnosis gaps and uneven psychiatric service distribution continue to shape treatment uptake, particularly outside major cities. The GCC is advancing through healthcare modernization, insurance expansion, and investment in specialized behavioral health services, creating stronger pathways for OCD diagnosis and pharmacological treatment while cultural stigma remains an important consideration.

The European Union provides a structured environment for OCD drug access through centralized regulatory standards, pharmacovigilance systems, and national reimbursement mechanisms. Its emphasis on mental health policy, patient safety, and real-world evidence supports consistent therapeutic evaluation across member states, even as reimbursement timelines differ. BRICS economies collectively represent diverse OCD drug dynamics, with China and India facing large access and affordability challenges, Brazil strengthening public and private mental health delivery, Russia maintaining a specialist-led treatment environment, and South Africa confronting workforce and equity constraints.

The G7 group is characterized by advanced regulatory systems, established clinical guidelines, high adoption of evidence-based psychiatric medicines, and strong post-marketing safety expectations, making it influential in clinical standards for OCD therapeutics. NATO countries overlap significantly with advanced North American and European healthcare systems, where mental health preparedness, service resilience, essential medicine availability, and pharmaceutical supply continuity are increasingly relevant policy considerations. Across these groups, the shared strategic themes are affordability, guideline-based prescribing, treatment-resistant OCD management, real-world outcomes, pharmacovigilance, and integration of medication with behavioral therapy.

Key Country Insights in Obsessive-Compulsive Disorder Drug Adoption

The United States remains a highly influential country for obsessive-compulsive disorder drugs due to strong clinical research activity, broad use of guideline-supported SSRIs, high telepsychiatry adoption, and active attention to treatment-resistant OCD. Access is shaped by insurance coverage, prior authorization, specialist availability, and high comorbidity management needs. Canada emphasizes publicly guided healthcare access, evidence-based prescribing, and mental health service integration, though provincial variation and regional disparities in psychiatric care influence timely treatment. Mexico is seeing expanding awareness and use of affordable generic medicines, while access to specialists and continuity of care remain uneven.

Brazil has a significant role in Latin American OCD treatment through its public health system and private sector, with antidepressant access supported by generic availability but constrained by regional disparities. The United Kingdom relies on structured clinical guidance, primary care pathways, and specialist mental health services, with stepped-care models supporting pharmacological and psychological treatment. Germany, France, Italy, and Spain maintain mature psychiatric prescribing environments, broad access to established OCD medications, and strong safety oversight, although waiting times for psychotherapy can affect integrated care. Russia has specialist psychiatric infrastructure and established antidepressant use, but regional access variation affects consistency of care.

China is experiencing rising mental health recognition, urban psychiatric service expansion, and growing use of evidence-based pharmacotherapy, while rural access and stigma remain barriers. India faces substantial unmet need because of diagnosis delays, limited specialist density, and affordability concerns, yet generic drug availability and digital health expansion are improving reach. Japan has a well-developed healthcare system and structured prescribing practices, with continued focus on safety and tolerability. Australia combines evidence-based mental health policy, primary care involvement, and telehealth-supported access, especially for geographically dispersed populations. South Korea is advancing mental health service capacity and digital care adoption, while stigma and high academic and occupational stress environments influence care-seeking behavior.

Actionable Recommendations for OCD Drug Industry Leaders

Industry leaders should prioritize differentiated therapeutic profiles that address the most persistent unmet needs in obsessive-compulsive disorder treatment, including inadequate response, delayed onset of benefit, relapse prevention, sexual dysfunction, weight change, sedation, and adherence challenges. Development programs should incorporate validated OCD-specific endpoints, patient-reported outcomes, comorbidity assessment, safety monitoring, and longer follow-up designs to demonstrate real-world clinical relevance.

Stakeholders should invest in precision psychiatry capabilities, including biomarker exploration, digital phenotyping, and AI-supported patient stratification, while maintaining rigorous ethical and regulatory standards. Partnerships with clinical networks can improve recruitment of diverse patient populations, including adolescents, adults with comorbid depression or anxiety, and individuals with treatment-resistant symptoms. Commercial and access teams should strengthen education for primary care physicians, psychiatrists, pharmacists, and caregivers to improve early diagnosis and guideline-concordant treatment.

Regional strategies should reflect local realities: affordability and generic access are critical in emerging economies, while evidence differentiation and health-economic justification are increasingly important in highly regulated markets. Leaders should also support integrated treatment models that combine medication with cognitive behavioral therapy, adherence tools, relapse monitoring, and culturally appropriate patient engagement. Supply resilience, pharmacovigilance, transparent evidence communication, and responsible digital integration will remain essential to sustaining trust in OCD pharmacotherapy.

Research Methodology for Evidence-Based OCD Drug Analysis

This executive summary is developed using a structured secondary research methodology grounded in verified public and scientific sources. The research approach synthesizes evidence from peer-reviewed psychiatric literature, clinical practice guidelines, regulatory agency communications, pharmacovigilance resources, public health publications, essential medicines references, and mental health policy documentation. Emphasis is placed on data-backed insights related to disease burden, treatment standards, drug classes, access dynamics, regulatory considerations, and regional healthcare infrastructure.

The analysis applies triangulation across clinical, regulatory, and health-system evidence to ensure consistency and reliability. Information is evaluated for source credibility, recency, therapeutic relevance, and applicability to obsessive-compulsive disorder pharmacotherapy. Regional, group, and country insights are interpreted through healthcare access, reimbursement, psychiatric workforce availability, mental health awareness, medicine availability, and telehealth adoption rather than market sizing or forecasting. The methodology excludes speculative estimates and avoids unsupported claims, focusing instead on observable treatment trends, evidence-based clinical practice, and policy-relevant market dynamics.

Conclusion on the Future of Obsessive-Compulsive Disorder Drugs

The obsessive-compulsive disorder drugs landscape is advancing from a conventional serotonin-centered treatment model toward a more integrated and patient-specific therapeutic ecosystem. Established medications remain essential, but the next phase of industry progress will be defined by better management of treatment-resistant OCD, improved tolerability, faster and more durable response, real-world evidence generation, and stronger coordination between pharmacotherapy and behavioral interventions.

Regional differences in access, stigma, affordability, specialist capacity, and reimbursement will continue to shape adoption patterns. Artificial intelligence, digital monitoring, and precision psychiatry can enhance research and care delivery when supported by clinical validation and responsible data governance. For industry participants, the most sustainable opportunities lie in clinically meaningful innovation, inclusive evidence generation, ethical technology use, pharmacovigilance strength, and access strategies that reflect local healthcare realities. By addressing unmet patient needs while aligning with evolving standards of mental health care, stakeholders can contribute to more effective and equitable OCD treatment worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Obsessive-Compulsive Disorder Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. MAOIs
    • 7.2.1. Phenelzine
    • 7.2.2. Tranylcypromine
  • 7.3. SNRIs
    • 7.3.1. Desvenlafaxine
    • 7.3.2. Duloxetine
    • 7.3.3. Venlafaxine
  • 7.4. SSRIs
    • 7.4.1. Citalopram
    • 7.4.2. Fluoxetine
    • 7.4.3. Fluvoxamine
    • 7.4.4. Paroxetine
    • 7.4.5. Sertraline
  • 7.5. TCAs
    • 7.5.1. Amitriptyline
    • 7.5.2. Clomipramine
    • 7.5.3. Imipramine

8. Obsessive-Compulsive Disorder Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online
    • 8.3.1. eCommerce Website
    • 8.3.2. Manufacturer Website

9. Obsessive-Compulsive Disorder Drugs Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral

10. Obsessive-Compulsive Disorder Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals
  • 10.4. Households

11. Obsessive-Compulsive Disorder Drugs Market, by Therapy Type

  • 11.1. Introduction
  • 11.2. Monotherapy
  • 11.3. Combination Therapy
  • 11.4. Adjunctive Therapy

12. Obsessive-Compulsive Disorder Drugs Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Obsessive-Compulsive Disorder Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Obsessive-Compulsive Disorder Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc
  • 16.2. Alembic Pharmaceuticals Ltd
  • 16.3. Amneal Pharmaceuticals Inc
  • 16.4. Apotex Inc
  • 16.5. AstraZeneca PLC
  • 16.6. Aurobindo Pharma Limited
  • 16.7. Biogen Inc
  • 16.8. Biohaven Ltd
  • 16.9. Bristol-Myers Squibb Company
  • 16.10. Cipla Limited
  • 16.11. Dr Reddys Laboratories Ltd
  • 16.12. Eli Lilly and Company
  • 16.13. GlaxoSmithKline plc
  • 16.14. Glenmark Pharmaceuticals Limited
  • 16.15. H Lundbeck AS
  • 16.16. Intas Pharmaceuticals Limited
  • 16.17. Jazz Pharmaceuticals Plc
  • 16.18. Johnson & Johnson
  • 16.19. Lupin Ltd
  • 16.20. Merck & Co Inc
  • 16.21. Novartis AG
  • 16.22. Otsuka Pharmaceutical Co Ltd
  • 16.23. Pfizer Inc
  • 16.24. Sun Pharmaceutical Industries Ltd
  • 16.25. Takeda Pharmaceutical Company Limited
  • 16.26. Teva Pharmaceutical Industries Ltd
  • 16.27. Torrent Pharmaceuticals Limited
  • 16.28. Viatris Inc
  • 16.29. Wockhardt Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MAOIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MAOIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MAOIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHENELZINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHENELZINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHENELZINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANYLCYPROMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANYLCYPROMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANYLCYPROMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SNRIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SNRIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SNRIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DESVENLAFAXINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DESVENLAFAXINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DESVENLAFAXINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DULOXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DULOXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DULOXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VENLAFAXINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VENLAFAXINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VENLAFAXINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SSRIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SSRIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SSRIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CITALOPRAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CITALOPRAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CITALOPRAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FLUOXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FLUOXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FLUOXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FLUVOXAMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FLUVOXAMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FLUVOXAMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PAROXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PAROXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PAROXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SERTRALINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SERTRALINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SERTRALINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TCAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TCAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TCAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AMITRIPTYLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMITRIPTYLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AMITRIPTYLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CLOMIPRAMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CLOMIPRAMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLOMIPRAMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMIPRAMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMIPRAMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMIPRAMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ECOMMERCE WEBSITE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ECOMMERCE WEBSITE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ECOMMERCE WEBSITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MANUFACTURER WEBSITE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MANUFACTURER WEBSITE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MANUFACTURER WEBSITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOUSEHOLDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOUSEHOLDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOUSEHOLDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ADJUNCTIVE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADJUNCTIVE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ADJUNCTIVE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 326. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 327. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 333. SPAIN OBSESSIVE-COMPULSIVE DISOR